JP2024544523A5 - - Google Patents
Info
- Publication number
- JP2024544523A5 JP2024544523A5 JP2024527460A JP2024527460A JP2024544523A5 JP 2024544523 A5 JP2024544523 A5 JP 2024544523A5 JP 2024527460 A JP2024527460 A JP 2024527460A JP 2024527460 A JP2024527460 A JP 2024527460A JP 2024544523 A5 JP2024544523 A5 JP 2024544523A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- stable aqueous
- aqueous pharmaceutical
- composition according
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277885P | 2021-11-10 | 2021-11-10 | |
| US63/277,885 | 2021-11-10 | ||
| PCT/US2022/079535 WO2023086817A1 (en) | 2021-11-10 | 2022-11-09 | Stable formulations comprising a bispecific bcma/cd3 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544523A JP2024544523A (ja) | 2024-12-03 |
| JP2024544523A5 true JP2024544523A5 (https=) | 2025-11-17 |
Family
ID=86336796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527460A Pending JP2024544523A (ja) | 2021-11-10 | 2022-11-09 | 二重特異性ｂｃｍａ／ｃｄ３抗体を含む安定な製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230279136A1 (https=) |
| EP (1) | EP4430082A4 (https=) |
| JP (1) | JP2024544523A (https=) |
| KR (1) | KR20240099432A (https=) |
| CN (1) | CN118251417A (https=) |
| AU (1) | AU2022383848A1 (https=) |
| CA (1) | CA3238152A1 (https=) |
| IL (1) | IL312700A (https=) |
| MX (1) | MX2024005727A (https=) |
| TW (1) | TW202328209A (https=) |
| WO (1) | WO2023086817A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005392A (es) | 2021-11-03 | 2024-08-06 | Janssen Biotech Inc | Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3. |
| WO2024044548A1 (en) * | 2022-08-23 | 2024-02-29 | Janssen Biotech, Inc. | Teclistamab for the treatment of multiple myeloma |
| WO2024044545A1 (en) * | 2022-08-23 | 2024-02-29 | Janssen Biotech, Inc. | Approved products for the treatment of multiple myeloma |
| WO2024231860A1 (en) * | 2023-05-09 | 2024-11-14 | Janssen Biotech, Inc. | Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| CN121712524A (zh) * | 2023-08-18 | 2026-03-20 | 百时美施贵宝公司 | 包含结合bcma和cd3的抗体的组合物以及治疗方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2635352C (en) * | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| UA130542C2 (uk) * | 2018-05-16 | 2026-03-18 | Янссен Байотек, Інк. | Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта |
| US11591395B2 (en) * | 2019-04-19 | 2023-02-28 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti-PSMA/CD3 antibody |
-
2022
- 2022-11-09 KR KR1020247018754A patent/KR20240099432A/ko active Pending
- 2022-11-09 IL IL312700A patent/IL312700A/en unknown
- 2022-11-09 AU AU2022383848A patent/AU2022383848A1/en active Pending
- 2022-11-09 EP EP22893801.5A patent/EP4430082A4/en active Pending
- 2022-11-09 CA CA3238152A patent/CA3238152A1/en active Pending
- 2022-11-09 CN CN202280074899.4A patent/CN118251417A/zh active Pending
- 2022-11-09 US US18/053,904 patent/US20230279136A1/en active Pending
- 2022-11-09 JP JP2024527460A patent/JP2024544523A/ja active Pending
- 2022-11-09 MX MX2024005727A patent/MX2024005727A/es unknown
- 2022-11-09 TW TW111142782A patent/TW202328209A/zh unknown
- 2022-11-09 WO PCT/US2022/079535 patent/WO2023086817A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024544523A5 (https=) | ||
| JP2024016177A5 (https=) | ||
| JP2023540025A5 (https=) | ||
| JP2022532927A5 (https=) | ||
| FI4249512T3 (fi) | Stabiili vasta-aineformulaatio | |
| JP2024514344A5 (https=) | ||
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| JP2020518598A5 (https=) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2016534052A5 (https=) | ||
| JP2024506940A5 (https=) | ||
| JP2024515968A5 (https=) | ||
| JP2024531151A5 (https=) | ||
| AR124067A2 (es) | Formulaciones estables que comprenden un anticuerpo biespecífico para egfr / c-met | |
| CN113797333A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| AR126614A1 (es) | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma | |
| JP2025500784A5 (https=) | ||
| WO2023186173A1 (zh) | 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法 | |
| CN117159703B (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| JP2023535433A (ja) | Ｐｄ－ｌ１／ｌａｇ－３二重特異性抗体製剤およびその調製方法ならびに使用 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2023502398A5 (https=) | ||
| JP2024538140A5 (https=) | ||
| KR101581517B1 (ko) | Tgf-알파 및 에피레굴린에 결합하는 항체 | |
| AR130130A1 (es) | Proteínas de unión al receptor de transferrina para tratar tumores cerebrales |